President & CIO Mayukh Sukhatme Sells $24.2M in Roivant Shares
ROIV has more than doubled off its 52-week low of $11.54.
Summary
Roivant's President and CIO sold $24.2M in shares over four days, adding to a $34M sale in June. The insider has now sold over $58M in 90 days.
Key Events · Ownership and Investor Activity · ROIV
-
President Sells $24.2M in Shares
Mayukh Sukhatme sold 664,826 shares at prices between $36.10 and $37.30, totaling $24.16M, between August 14 and 18.
-
Options Exercised at $3.85
The sales were preceded by exercising 664,826 options at $3.85 per share, yielding a cost basis of $2.56M and a profit of approximately $21.6M.
-
Repeated Insider Selling
This follows a $34M sale by Sukhatme on June 29, bringing his 90-day open market sales to over $58M.
-
Near 52-Week High
Sales occurred with the stock trading near its 52-week high of $37.46, indicating potential profit-taking.
Analysis · ROIV · Life Sciences
Mayukh Sukhatme, Roivant's President and CIO, sold $24.2 million of common shares between August 14 and 18, exercising options at $3.85 and selling at prices from $36.10 to $37.30. This follows a $34 million sale by the same insider in late June, bringing his 90-day open market sales to over $58 million. The sales occur near the stock's 52-week high of $37.46, suggesting profit-taking after a strong run. While the transaction represents only 0.099% of market cap, the pattern of repeated large sales by a key executive is notable for investors.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $37.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27B. The 52-week trading range was $11.54 to $37.46. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.